News
In the early trading on Tuesday, US stocks saw Novo Nordisk rise by 2.1%. The pharmaceutical company announced that its experimental weekly weight loss drug Cagrilintide single-agent injection helped patients lose 11.8% of their body weight over 68 weeks
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments